Stuart Rich

List of Publications by Citations

96 papers	18,127 citations	55 h-index	100 g-index
100 ext. papers	20,326 ext. citations	8 avg, IF	6.09 L-index

#	Paper	IF	Citations
96	A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. *New England Journal of Medicine*, **1996**, 334, 296-301	59.2	2125
95	Primary pulmonary hypertension. A national prospective study. *Annals of Internal Medicine*, **1987**, 107, 216-23	8	1405
94	The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. *New England Journal of Medicine*, **1992**, 327, 76-81	59.2	1209
93	Clinical classification of pulmonary hypertension. *Journal of the American College of Cardiology*, **2004**, 43, 5S-12S	15.1	1162
92	Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 800-4	10.2	1041
91	Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. *New England Journal of Medicine*, **1996**, 335, 609-16	59.2	962
90	Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. *Circulation*, **2002**, 106, 1477-82	16.7	895
89	Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. *Annals of Internal Medicine*, **2000**, 132, 425-34	8	710
88	Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. *New England Journal of Medicine*, **1998**, 338, 273-7	59.2	552
87	Beraprost therapy for pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2003**, 41, 2119-25	15.1	460
86	Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: a multicenter study. *Circulation*, **1996**, 93, 898-904	16.7	358
85	Pulmonary arterial hypertension: epidemiology and registries. *Journal of the American College of Cardiology*, **2013**, 62, D51-9	15.1	338
84	Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35,246 adults. *American Journal of Cardiology*, **2001**, 87, 1335-9	3	333
83	Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". *Circulation*, **2000**, 102, 2781-91	16.7	309
82	Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. *American Journal of Physiology - Heart and Circulatory Physiology*, **2008**, 294, H570-8	5.2	272
81	The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. *Chest*, **1998**, 114, 787-92	5.3	263
80	Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. *Chest*, **2011**, 139, 988-993	5.3	260

79	Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. *Journal of the American College of Cardiology*, **1995**, 26, 1581-5	15.1	250
78	Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. *Circulation*, **1997**, 95, 1479-86	16.7	214
77	Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. *Circulation: Heart Failure*, **2011**, 4, 257-65	7.6	212
76	Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. *Chest*, **2014**, 146, 449-475	5.3	200
75	Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. *Chest*, **2004**, 126, 420-7	5.3	187
74	Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. *Journal of Cardiovascular Pharmacology*, **2003**, 41, 293-9	3.1	184
73	Endothelin receptor blockers in cardiovascular disease. *Circulation*, **2003**, 108, 2184-90	16.7	179
72	Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. *Chest*, **2002**, 121, 1860-8	5.3	174
71	Doppler echocardiographic assessment of impaired left ventricular filling in patients with right ventricular pressure overload due to primary pulmonary hypertension. *Journal of the American College of Cardiology*, **1986**, 8, 1298-306	15.1	163
70	The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. *The American Review of Respiratory Disease*, **1989**, 140, 1623-30		160
69	Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. *Chest*, **2000**, 117, 870-4	5.3	157
68	The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. *Journal of the American College of Cardiology*, **1999**, 34, 1184-7	15.1	147
67	Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2008**, 27, 668-74	5.8	136
66	Primary pulmonary hypertension. *Progress in Cardiovascular Diseases*, **1988**, 31, 205-38	8.5	127
65	Reproducibility of the measurement of coronary calcium with ultrafast computed tomography. *American Journal of Cardiology*, **1995**, 75, 973-5	3	121
64	Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. *Circulation*, **2006**, 113, 2509-15	16.7	119
63	Pressure and volume loading of the right ventricle have opposite effects on left ventricular ejection fraction. *Circulation*, **1995**, 92, 819-24	16.7	119
62	Doppler echocardiographic demonstration of the differential effects of right ventricular pressure and volume overload on left ventricular geometry and filling. *Journal of the American College of Cardiology*, **1992**, 19, 84-90	15.1	117

61	Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension. *American Journal of Cardiology*, **1985**, 55, 159-63	3	106
60	Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension. *American Journal of Medicine*, **1984**, 76, 573-8	2.4	94
59	Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. *Circulation*, **2008**, 117, 2475-83	16.7	93
58	Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku. *American Journal of Medicine*, **1992**, 93, 307-12	2.4	93
57	Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. *Chest*, **2010**, 138, 1234-9	5.3	88
56	Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. *American Heart Journal*, **2010**, 159, 245-57	4.9	85
55	Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. *American Journal of Cardiology*, **1997**, 80, 369-71	3	85
54	Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. *Circulation*, **2008**, 118, 2190-9	16.7	83
53	Clinical diagnosis of pulmonary hypertension. *Circulation*, **2014**, 130, 1820-30	16.7	79
52	Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. *Circulation*, **2008**, 118, 1195-201	16.7	78
51	Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. *Journal of the American College of Cardiology*, **1992**, 19, 1060-4	15.1	78
50	Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. *American Journal of Cardiology*, **2005**, 96, 1334-6	3	76
49	Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. *Chest* , **1995**, 107, 54-7	5.3	75
48	Understanding right and left ventricular systolic function and interactions at rest and with exercise in primary pulmonary hypertension. *American Journal of Cardiology*, **1995**, 75, 374-7	3	70
47	The current treatment of pulmonary arterial hypertension: time to redefine success. *Chest*, **2006**, 130, 1198-202	5.3	69
46	High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. *Journal of the American College of Cardiology*, **1991**, 18, 1323-7	15.1	68
45	Temporal trends and drug exposures in pulmonary hypertension: an American experience. *American Heart Journal*, **2006**, 152, 521-6	4.9	65
44	The effects of phenylephrine on right ventricular performance in patients with pulmonary hypertension. *Chest*, **1990**, 98, 1102-6	5.3	64

43	Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. *Annals of Internal Medicine*, **1986**, 105, 499-502	8	64
42	Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. *Circulation*, **2015**, 131, 401-9; discussion 409	16.7	60
41	Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. *American Heart Journal*, **2002**, 143, E4	4.9	54
40	Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 464-75	10.2	52
39	The prevalence and significance of a patent foramen ovale in pulmonary hypertension. *Chest*, **1993**, 104, 1673-5	5.3	50
38	Stenting to reverse left ventricular ischemia due to left main coronary artery compression in primary pulmonary hypertension. *Chest*, **2001**, 120, 1412-5	5.3	49
37	Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2010**, 29, 181-7	5.8	45
36	Tricuspid regurgitation progression and regression in pulmonary arterial hypertension: implications for right ventricular and tricuspid valve apparatus geometry and patients outcome. *European Heart Journal Cardiovascular Imaging*, **2017**, 18, 86-94	4.1	44
35	Noninvasive cardiac output measurements in patients with pulmonary hypertension. *European Respiratory Journal*, **2013**, 42, 125-33	13.6	44
34	Clinical insights into the pathogenesis of primary pulmonary hypertension. *Chest*, **1998**, 114, 237S-241S	5.3	44
33	Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. *Chest*, **2009**, 136, 694-700	5.3	38
32	Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2002**, 30, 191-5	3.1	38
31	Right ventricular adaptation and maladaptation in chronic pulmonary arterial hypertension. *Cardiology Clinics*, **2012**, 30, 257-69	2.5	34
30	Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension. *Journal of the American College of Cardiology*, **1993**, 21, 413-8	15.1	32
29	Medical treatment of primary pulmonary hypertension: a bridge to transplantation?. *American Journal of Cardiology*, **1995**, 75, 63A-66A	3	31
28	Detection of subclinical cardiovascular disease: the emerging role of electron beam computed tomography. *Preventive Medicine*, **2002**, 34, 1-10	4.3	30
27	Successful management of labor and delivery in primary pulmonary hypertension. *American Journal of Cardiology*, **1993**, 71, 1124-5	3	28
26	Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension. *Histopathology*, **2012**, 61, 597-609	7.3	25

25	Familial pulmonary hypertension in association with an abnormal hemoglobin. Insights into the pathogenesis of primary pulmonary hypertension. *Chest*, **1991**, 99, 1208-10	5.3	23
24	Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension. *American Journal of Cardiology*, **2003**, 92, 1366-8	3	21
23	The effects of vasodilators in pulmonary hypertension: pulmonary vascular or peripheral vascular?. *Circulation: Heart Failure*, **2009**, 2, 145-50	7.6	19
22	Relation between hormone replacement therapy in women and coronary artery disease estimated by electron beam tomography. *American Heart Journal*, **1997**, 134, 1115-9	4.9	19
21	Development of nonspecific interstitial pneumonitis associated with long-term treatment of primary pulmonary hypertension with prostacyclin. *Chest*, **1999**, 116, 566-9	5.3	17
20	Pulmonary hypertension. *Current Problems in Cardiology*, **2004**, 29, 575-634	17.1	16
19	What is pulmonary arterial hypertension?. *Pulmonary Circulation*, **2012**, 2, 271-2	2.7	15
18	Pulmonary hypertension: the unaddressed global health burden. *Lancet Respiratory Medicine,the*, **2018**, 6, 577-579	35.1	13
17	The medical treatment of primary pulmonary hypertension. Proven and promising strategies. *Chest*, **1994**, 105, 17S-20S	5.3	12
16	Primary Pulmonary Hypertension. *Current Treatment Options in Cardiovascular Medicine*, **2000**, 2, 135-140	2.1	11
15	The role of thrombosis in pulmonary hypertension. *Chest*, **1993**, 103, 660-1	5.3	11
14	Short-term effectiveness of nifedipine in secondary pulmonary hypertension. *American Journal of Cardiology*, **1993**, 71, 1475-6	3	11
13	Targeting pulmonary vascular disease to improve global health: pulmonary vascular disease: the global perspective. *Chest*, **2010**, 137, 1S-5S	5.3	8
12	Are anticoagulants still indicated in pulmonary arterial hypertension?. *Pulmonary Circulation*, **2018**, 8, 2045894018807681	2.7	8
11	Severe pulmonary hypertension: critical care clinics. *Critical Care Clinics*, **2001**, 17, 453-67	4.5	7
10	Lung transplantation for pulmonary hypertension: patient selection and maintenance therapy while awaiting transplantation. *Seminars in Thoracic and Cardiovascular Surgery*, **1998**, 10, 135-8	1.7	7
9	Serum nifedipine concentrations and response of patients with pulmonary hypertension. *American Journal of Cardiology*, **1996**, 77, 996-9	3	7
8	Future of clinical trials for pulmonary hypertension. *Circulation*, **2011**, 123, 2919-21	16.7	5

List of Publications

7	A New Classification of Pulmonary Hypertension. *Advances in Pulmonary Hypertension*, **2002**, 1, 3-6	0.5	5
6	The pulmonary hypertension academic research consortium. *Pulmonary Circulation*, **2013**, 3, 203-5	2.7	3
5	How do we explain unexplained pulmonary hypertension in the elderly?. *Chest*, **2007**, 131, 5-6	5.3	3
4	Prostacyclin and primary pulmonary hypertension. *Annals of Internal Medicine*, **1994**, 121, 463-4	8	2
3	Lung transplantation for pulmonary hypertension: patient selection and maintenance therapy while awaiting transplantation. *Transplantation Reviews*, **1998**, 12, 205-208	3.3	
2	The Cellular Basis of the Pathophysiology and Treatment of Pulmonary Hypertension **1996**, 175-180		
1	Calcium Channel Blockers in the Treatment of Pulmonary Arterial Hypertension **2011**, 1447-1450		